A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation

Background: Drugs that exhibit close margins between therapeutic and toxic blood concentrations are considered to have a narrow therapeutic index (NTI). The Food and Drug Administration has proposed that NTI drugs should have more stringent bioequivalence standards for approval of generic formulations. However, many immunosuppressant drugs do not have a well-defined therapeutic index (TI). Methods: We sought to determine whether safety, efficacy, and pharmacokinetic data obtained from the medical literature through a comprehensive literature search could be used to estimate the TI of cyclosporine, tacrolimus, and sirolimus. In this analysis, we considered TI ⩽2 as a criterion to define a drug as having an NTI. Results: Published literature indicates that cyclosporine has a TI of 2–3, which falls just short of our criteria to be classified as having an NTI. We found sirolimus and tacrolimus to have a therapeutic range of 5–12 ng/mL and of 5–20 ng/mL, respectively, but were unable to calculate the TI. Conclusions: Although the current literature does not provide a clear indication that these drugs have an NTI, the routine use of therapeutic drug monitoring in clinical practice suggests that more stringent testing of their pharmacokinetic and pharmacodynamic properties should be performed before the approval of generic formulations.

[1]  F. Huang,et al.  Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation , 2016, American journal of therapeutics.

[2]  Lawrence X. Yu,et al.  Erratum to: A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion , 2015, The AAPS Journal.

[3]  Asif Khan,et al.  Fungal Infections in Renal Transplant Patients , 2015, Journal of clinical medicine research.

[4]  R Lionberger,et al.  Novel bioequivalence approach for narrow therapeutic index drugs , 2015, Clinical pharmacology and therapeutics.

[5]  P. Bárány,et al.  Systematic conversion to generic tacrolimus in stable kidney transplant recipients , 2014, Clinical kidney journal.

[6]  J. Azzi,et al.  Calcineurin Inhibitors: 40 Years Later, Can’t Live Without … , 2013, The Journal of Immunology.

[7]  J. Cortelli,et al.  Gingival Overgrowth in Renal Transplant Subjects: A 44-Month Follow-Up Study , 2013, Transplantation.

[8]  S. Kulkarni,et al.  Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  A. Johnston,et al.  Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation , 2013, European journal of hospital pharmacy. Science and practice.

[10]  G. Russ,et al.  A Randomized, Open-Label Study of Sirolimus Versus Cyclosporine in Primary De Novo Renal Allograft Recipients , 2013, Transplantation.

[11]  S. Mulgaonkar,et al.  Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  R. Lee,et al.  Current trends in immunosuppressive therapies for renal transplant recipients. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  David W. Johnson,et al.  Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[14]  M. Shakeri,et al.  Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation. , 2012, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[15]  J. D. de Fijter,et al.  Randomized Trial Comparing Late Concentration-Controlled Calcineurin Inhibitor or Mycophenolate Mofetil Withdrawal , 2012, Transplantation.

[16]  M. Christiaans,et al.  Everolimus plus early tacrolimus minimization: a phase III, randomized, open‐label, multicentre trial in renal transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[17]  T. Keough-Ryan,et al.  Generic Immunosuppression in Solid Organ Transplantation: A Canadian Perspective , 2012, Transplantation.

[18]  B. Banas,et al.  Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[19]  R. Alloway,et al.  Immunosuppression, Generic Drugs and the FDA , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  K. Huh,et al.  Sirolimus-induced pneumonitis after renal transplantation: a single-center experience. , 2012, Transplantation proceedings.

[21]  Y. S. Kim,et al.  A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. , 2012, Transplantation proceedings.

[22]  E. Tichy,et al.  A Multicenter Experience With Generic Tacrolimus Conversion , 2011, Transplantation.

[23]  A. Humar,et al.  The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With Stable Graft Function , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  S. Mulgaonkar,et al.  Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. , 2011, Kidney international.

[25]  Thomas Becker,et al.  Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial , 2011, The Lancet.

[26]  S. Hatami,et al.  Gingival enlargement and its risk factors in kidney transplant patients receiving cyclosporine A. , 2010, Iranian journal of kidney diseases.

[27]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  J. Joh,et al.  Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living‐donor renal transplantation: 5‐year follow‐up , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[29]  K. Chau,et al.  Long‐term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis , 2009, Nephrology.

[30]  V. Meas-Yedid,et al.  Interstitial Fibrosis Quantification in Renal Transplant Recipients Randomized to Continue Cyclosporine or Convert to Sirolimus , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  Lawrence X. Yu,et al.  Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration , 2009, The Annals of pharmacotherapy.

[32]  C. O’Seaghdha,et al.  Higher tacrolimus trough levels on days 2–5 post‐renal transplant are associated with reduced rates of acute rejection , 2009, Clinical transplantation.

[33]  B. Krämer.  Tacrolimus prolonged release in kidney transplantation , 2009, Expert review of clinical immunology.

[34]  Minnie Sarwal,et al.  Calcineurin Inhibitor Nephrotoxicity , 2012 .

[35]  F. Schena,et al.  Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial , 2009, Transplantation.

[36]  A. Gaber,et al.  Comparison of Sirolimus Plus Tacrolimus Versus Sirolimus Plus Cyclosporine in High-Risk Renal Allograft Recipients: Results From an Open-Label, Randomized Trial , 2008, Transplantation.

[37]  J. A. Al Wakeel,et al.  Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral. , 2008, Transplantation proceedings.

[38]  A. Henning,et al.  Optimizing Tacrolimus Therapy in the Maintenance of Renal Allografts: 12-Month Results , 2008, Transplantation.

[39]  C. Ronco,et al.  Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  A. Shokeir,et al.  Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience. , 2008, Iranian journal of kidney diseases.

[41]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[42]  R. Viebahn,et al.  Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  P. Kuo,et al.  One‐Year Results with Extended‐Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  Edward Cole,et al.  Therapeutic monitoring of calcineurin inhibitors for the nephrologist. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[45]  T. Larson,et al.  Comparison of Low Versus High Tacrolimus Levels in Kidney Transplantation: Assessment of Efficacy by Protocol Biopsies , 2007, Transplantation.

[46]  Kim-Ming Wong,et al.  Paired kidney analysis of tacrolimus and cyclosporine microemulsion‐based therapy in Chinese cadaveric renal transplant recipients , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[47]  A. Barbari,et al.  Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study. , 2006, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[48]  D. Abramowicz,et al.  Tacrolimus Combined with Two Different Dosages of Sirolimus in Kidney Transplantation: Results of a Multicenter Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[49]  J. Rogers,et al.  Does Bioequivalence Between Modified Cyclosporine Formulations Translate into Equal Outcomes? , 2005, Transplantation.

[50]  G. Russ,et al.  Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function , 2005, Transplantation.

[51]  M. Ghoneim,et al.  Comparison of Sirolimus with Low‐Dose Tacrolimus Versus Sirolimus‐based Calcineurin Inhibitor‐Free Regimen in Live Donor Renal Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  T. Waid.  Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure , 2005, Clinical transplantation.

[53]  F. Schena,et al.  Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. , 2005, Transplantation proceedings.

[54]  J. Till,et al.  Inflation Targets Versus International Monetary Integration - a Canadian Perspective , 2002, SSRN Electronic Journal.

[55]  D. Kuypers.  Benefit-Risk Assessment of Sirolimus in Renal Transplantation , 2005, Drug safety.

[56]  F. Schena,et al.  Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: results at 3 years. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[57]  J. Joh,et al.  Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. , 2004, Transplantation proceedings.

[58]  P. Friend,et al.  Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies * , 2004, Clinical transplantation.

[59]  T. Larson,et al.  WOUND-HEALING COMPLICATIONS AFTER KIDNEY TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED COMPARISON OF SIROLIMUS AND TACROLIMUS1 , 2004, Transplantation.

[60]  B. Maes,et al.  Clinical Efficacy and Toxicity Profile of Tacrolimus and Mycophenolic Acid in Relation to Combined Long‐term Pharmacokinetics in de Novo Renal Allograft Recipients , 2004, Clinical pharmacology and therapeutics.

[61]  L. Gaber,et al.  Observations regarding the use of sirolimus and tacrolimus in high‐risk cadaveric renal transplantation , 2004, Clinical transplantation.

[62]  C. Dudley,et al.  Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients , 2003, Transplantation.

[63]  P. Keown,et al.  A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporin A , 2003 .

[64]  G. Russ,et al.  Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. , 2003, Transplantation proceedings.

[65]  P. Keown,et al.  A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001. , 2003, Clinical therapeutics.

[66]  B. Krämer,et al.  Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up. , 2002, Transplantation proceedings.

[67]  R. Margreiter.  Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study , 2002, The Lancet.

[68]  K. Salmela,et al.  Early cyclosporine concentration as predictor of graft survival in cadaveric renal transplantation. , 2001, Transplantation proceedings.

[69]  B. Kaplan,et al.  RAD IN DE NOVO RENAL TRANSPLANTATION: COMPARISON OF THREE DOSES ON THE INCIDENCE AND SEVERITY OF ACUTE REJECTION 1 , 2001, Transplantation.

[70]  H. Sperschneider.  A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. , 2001, Transplantation proceedings.

[71]  A. Macdonald.  A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS , 2001, Transplantation.

[72]  J. Podbielski,et al.  Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity , 2000, Clinical transplantation.

[73]  B. Julian,et al.  Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. , 1999, Transplantation.

[74]  G. Tydén,et al.  Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. , 1999, British journal of clinical pharmacology.

[75]  M. Choc.  Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs Sandimmune® , 1997, International journal of dermatology.

[76]  D Talbot,et al.  Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. , 1997, Transplantation.

[77]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[78]  J. Pirsch,et al.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. , 1997, Transplantation.

[79]  P. Reinke,et al.  Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. , 1996, International journal of clinical pharmacology and therapeutics.

[80]  A. Matas,et al.  An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. , 1996, Transplantation.

[81]  R. Kershner,et al.  Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. , 1996, Transplantation.

[82]  C. Ponticelli,et al.  Randomized study with cyclosporine in kidney transplantation: 10-year follow-up. , 1996, Journal of the American Society of Nephrology : JASN.

[83]  M. Christiaans,et al.  FK 506 versus cyclosporin in the prevention of renal allograft rejection — European pilot study: six-week results , 1995 .

[84]  J. Pirsch,et al.  Long-term efficacy and safety of cyclosporine in renal-transplant recipients. , 1994, The New England journal of medicine.

[85]  B. Kahan,et al.  Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation , 1993, Clinical pharmacology and therapeutics.

[86]  D. Freeman.  Pharmacology and pharmacokinetics of cyclosporine. , 1991, Clinical biochemistry.

[87]  D. Holt,et al.  Value of cyclosporine measurements in renal transplant recipients immunosuppressed with triple therapy. , 1990, Transplantation proceedings.

[88]  B. Kasiske,et al.  The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. , 1988, Transplantation.

[89]  J. Najarian,et al.  Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: results of the Minnesota randomized trial comparing cyclosporine versus antilymphocyte globulin-azathioprine. , 1986, Transplantation proceedings.

[90]  A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. , 1986, The New England journal of medicine.

[91]  H. Sharma,et al.  Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. , 1985, American journal of surgery.